Highlight
– Bexotegrast, an oral dual αvβ6/αvβ1 integrin inhibitor, was well tolerated with mild to moderate adverse events in patients with PSC and liver fibrosis.
– Exploratory pharmacodynamic markers, including ELF score and MRI parameters, showed numerically less progression or improvement with bexotegrast versus placebo.
– The trial supports targeting integrin-mediated TGF-β activation as a novel therapeutic strategy in PSC.
– Further studies are needed to confirm clinical efficacy and long-term safety.
